Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 124

1.

Expression patterns of PAX5, c-Met, and paxillin in neuroendocrine tumors of the lung.

Song J, Li M, Tretiakova M, Salgia R, Cagle PT, Husain AN.

Arch Pathol Lab Med. 2010 Nov;134(11):1702-5. doi: 10.1043/2009-0664-OAR1.1.

2.

PAX5 is expressed in small-cell lung cancer and positively regulates c-Met transcription.

Kanteti R, Nallasura V, Loganathan S, Tretiakova M, Kroll T, Krishnaswamy S, Faoro L, Cagle P, Husain AN, Vokes EE, Lang D, Salgia R.

Lab Invest. 2009 Mar;89(3):301-14. doi: 10.1038/labinvest.2008.168. Epub 2009 Jan 12.

3.

Molecular and cellular biology of neuroendocrine lung tumors: evidence for separate biological entities.

Swarts DR, Ramaekers FC, Speel EJ.

Biochim Biophys Acta. 2012 Dec;1826(2):255-71. doi: 10.1016/j.bbcan.2012.05.001. Epub 2012 May 10. Review.

PMID:
22579738
4.

Divergent cyclin B1 expression and Rb/p16/cyclin D1 pathway aberrations among pulmonary neuroendocrine tumors.

Igarashi T, Jiang SX, Kameya T, Asamura H, Sato Y, Nagai K, Okayasu I.

Mod Pathol. 2004 Oct;17(10):1259-67.

5.

Alterations in the expression of p53, KLF4, and p21 in neuroendocrine lung tumors.

Naranjo Gómez JM, Bernal JF, Arranz PG, Fernández SL, Roman JJ.

Arch Pathol Lab Med. 2014 Jul;138(7):936-42. doi: 10.5858/arpa.2013-0119-OA.

PMID:
24978920
6.

Mammalian target of rapamycin signaling activation patterns in neuroendocrine tumors of the lung.

Righi L, Volante M, Rapa I, Tavaglione V, Inzani F, Pelosi G, Papotti M.

Endocr Relat Cancer. 2010 Oct 29;17(4):977-87. doi: 10.1677/ERC-10-0157. Print 2010 Dec.

7.

Promyelocytic leukemia zinc finger and histone H1.5 differentially stain low- and high-grade pulmonary neuroendocrine tumors: a pilot immunohistochemical study.

Hechtman JF, Beasley MB, Kinoshita Y, Ko HM, Hao K, Burstein DE.

Hum Pathol. 2013 Jul;44(7):1400-5. doi: 10.1016/j.humpath.2012.11.014. Epub 2013 Feb 14.

PMID:
23416030
8.

Alteration of the E-cadherin/beta-catenin cell adhesion system is common in pulmonary neuroendocrine tumors and is an independent predictor of lymph node metastasis in atypical carcinoids.

Pelosi G, Scarpa A, Puppa G, Veronesi G, Spaggiari L, Pasini F, Maisonneuve P, Iannucci A, Arrigoni G, Viale G.

Cancer. 2005 Mar 15;103(6):1154-64.

9.

[Expression and clinicopathologic significance of human achaete-scute homolog 1 in pulmonary neuroendocrine tumors].

Li F, Zhong Z, Li R, Huang H, Wang L, Zheng D, Zhang D.

Zhongguo Fei Ai Za Zhi. 2010 Apr;13(4):317-21. doi: 10.3779/j.issn.1009-3419.2010.04.09. Chinese.

10.

Immunohistochemical expression of estrogen and progesterone receptors in primary pulmonary neuroendocrine tumors.

Sica G, Wagner PL, Altorki N, Port J, Lee PC, Vazquez MF, Saqi A.

Arch Pathol Lab Med. 2008 Dec;132(12):1889-95. doi: 10.1043/1543-2165-132.12.1889.

PMID:
19061285
11.

Apoptosis-related factors p53, Bcl2, and Bax in neuroendocrine lung tumors.

Brambilla E, Negoescu A, Gazzeri S, Lantuejoul S, Moro D, Brambilla C, Coll JL.

Am J Pathol. 1996 Dec;149(6):1941-52.

12.

Analysis of p53, K-ras-2, and C-raf-1 in pulmonary neuroendocrine tumors. Correlation with histological subtype and clinical outcome.

Przygodzki RM, Finkelstein SD, Langer JC, Swalsky PA, Fishback N, Bakker A, Guinee DG, Koss M, Travis WD.

Am J Pathol. 1996 May;148(5):1531-41.

13.

Coexpression of c-kit and bcl-2 in small cell carcinoma and large cell neuroendocrine carcinoma of the lung.

LaPoint RJ, Bourne PA, Wang HL, Xu H.

Appl Immunohistochem Mol Morphol. 2007 Dec;15(4):401-6.

PMID:
18091382
14.

The oncofetal protein IMP3: a useful marker to predict poor clinical outcome in neuroendocrine tumors of the lung.

Del Gobbo A, Vaira V, Guerini Rocco E, Palleschi A, Bulfamante G, Ricca D, Fiori S, Bosari S, Ferrero S.

J Thorac Oncol. 2014 Nov;9(11):1656-61. doi: 10.1097/JTO.0000000000000316.

15.

Malignancy-associated X chromosome allelic losses in foregut endocrine neoplasms: further evidence from lung tumors.

D'Adda T, Bottarelli L, Azzoni C, Pizzi S, Bongiovanni M, Papotti M, Pelosi G, Maisonneuve P, Antonetti T, Rindi G, Bordi C.

Mod Pathol. 2005 Jun;18(6):795-805.

16.

Thyroid transcription factor-1: immunohistochemical evaluation in pulmonary neuroendocrine tumors.

Folpe AL, Gown AM, Lamps LW, Garcia R, Dail DH, Zarbo RJ, Schmidt RA.

Mod Pathol. 1999 Jan;12(1):5-8.

PMID:
9950155
17.

hASH1 is a specific immunohistochemical marker for lung neuroendocrine tumors.

Ye B, Cappel J, Findeis-Hosey J, McMahon L, Yang Q, Xiao GQ, Xu H, Li F.

Hum Pathol. 2016 Feb;48:142-7. doi: 10.1016/j.humpath.2015.09.019. Epub 2015 Oct 3.

PMID:
26596584
18.
19.

P63 expression in lung carcinoma: a tissue microarray study of 408 cases.

Au NH, Gown AM, Cheang M, Huntsman D, Yorida E, Elliott WM, Flint J, English J, Gilks CB, Grimes HL.

Appl Immunohistochem Mol Morphol. 2004 Sep;12(3):240-7.

PMID:
15551738
20.

Forkhead box A2 transcription factor is expressed in all types of neuroendocrine lung tumors.

Khoor A, Stahlman MT, Johnson JM, Olson SJ, Whitsett JA.

Hum Pathol. 2004 May;35(5):560-4.

PMID:
15138929

Supplemental Content

Support Center